StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
BTX stock opened at $5.88 on Tuesday. Brooklyn ImmunoTherapeutics has a 1 year low of $5.10 and a 1 year high of $8.31. The firm has a 50-day moving average of $5.63 and a 200 day moving average of $2.34. The company has a market cap of $345.90 million, a P/E ratio of -2.59 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Dividend Announcement
The company also recently declared a monthly dividend, which was paid on Monday, March 31st. Investors of record on Friday, March 14th were given a dividend of $0.0862 per share. The ex-dividend date was Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 17.58%. Brooklyn ImmunoTherapeutics’s dividend payout ratio is presently -44.05%.
About Brooklyn ImmunoTherapeutics
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Articles
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
